Perceptive Advisors LLC Has $47.46 Million Stake in CytomX Therapeutics, Inc. $CTMX

Perceptive Advisors LLC lifted its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,098,824 shares of the biotechnology company’s stock after buying an additional 418,639 shares during the quarter. CytomX Therapeutics comprises 0.9% of Perceptive Advisors LLC’s investment portfolio, making the stock its 26th largest holding. Perceptive Advisors LLC owned 0.06% of CytomX Therapeutics worth $47,464,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in CytomX Therapeutics by 1,064.3% during the first quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock valued at $47,953,000 after acquiring an additional 9,326,480 shares in the last quarter. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics in the second quarter worth approximately $19,208,000. Commodore Capital LP bought a new stake in CytomX Therapeutics in the second quarter worth approximately $17,462,000. State Street Corp increased its stake in shares of CytomX Therapeutics by 697.1% during the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock worth $21,900,000 after purchasing an additional 4,495,949 shares during the last quarter. Finally, Elmind Capital LP raised its holdings in shares of CytomX Therapeutics by 550.0% during the 1st quarter. Elmind Capital LP now owns 4,550,000 shares of the biotechnology company’s stock valued at $21,385,000 after purchasing an additional 3,850,000 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 5.5%

Shares of NASDAQ:CTMX opened at $3.10 on Friday. The company has a market cap of $527.59 million, a price-to-earnings ratio of -7.56 and a beta of 2.08. The business has a 50 day moving average price of $3.39 and a 200 day moving average price of $4.31. CytomX Therapeutics, Inc. has a twelve month low of $1.72 and a twelve month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%.The company had revenue of $10.26 million during the quarter, compared to analyst estimates of $4.68 million. Analysts anticipate that CytomX Therapeutics, Inc. will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CTMX shares. Wolfe Research initiated coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price objective for the company. Zacks Research raised CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Wall Street Zen upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. Finally, HC Wainwright lowered their target price on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CytomX Therapeutics has a consensus rating of “Buy” and an average target price of $12.10.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.